Answers are grounded in this paper and cite their sources.
Background: Serum homocysteine levels have been observed to be increased in sickle cell disease (SCD).The biological mechanism of synthesis and regulation of the homocysteine remains unclear.This meta-analysis aims to provide an overview of the serum homocysteine level changes and to discuss its significance in SCD. Materials and methods:This meta-analysis is to determine serum homocysteine level changes during SCD and was conducted under the PRISMA guidelines.Without language restrictions, the articles were identified through BioMed, Embase, Pub Med® (U.S. National Library of Medicine, USA), and www.Blood Journal.org,PLoS ONE, Web of Science, LILACS (Latin American and Caribbean Health Sciences Literature), ISI Web of Science, Chemical abstract services-(CAS), Europe PMC, Bio sis Previews, Elsevier Properties S.A., USA.The studies have been considered which were published before March 31, 2018.Results: Thirty comparative studies were identified out of 8,630 articles and included in the meta-analysis.From the final selected articles, the mean, standard deviation, sample size of cases vs controls were showing compared and calculated by the SPSS latest software version-24.From 30, 18 articles were statistically highly significant, and the remaining 12 articles were statistically not significant.The p <0.05 was considered to be statistically significant.The combined estimation of the meta-analysis study is highly significant, since p <0.000000, calculated "t" is 25.07, and degree of freedom is 2,829.Conclusion: The study concludes that there is an extremely significant difference between mean serum homocysteine levels in cases and healthy controls.So, the serum homocysteine level can be used as a clinical biomarker for the diagnosis of SCD.
No takes yet. Share an insight, caveat, or question.
Padhyegurjar et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: